Autopsy report · NCT04330625

Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“Lack of enrollment”

The sponsor’s own words in the registry.

Life of this trial

Registered 7 months before it started.
Ran for about 6 months before it stopped.
1 participant enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 1
Sponsor: Duke University
Sponsor type: University, hospital or other
Conditions: Hyperglycemia Drug Induced
Interventions: REMD-477
Participants: 1
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.